Nimotop
This medication is indicated for neurological recovery after subarachnoid haemorrhage utilized to mitigate vasospasm and support brain cell protection.
Strengths: 30mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Calcium Channel Blocker
- Pharmacological class
Dihydropyridine Calcium Channel Blocker
- Contraindications
hypersensitivity to nimodipine; concomitant use of rifampicin
- Precautions and warnings
may impair ability to drive or operate machinery; monitor blood pressure
- Minor side effects
headache; flushing
- Moderate side effects
hypotension; nausea; dizziness
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Bayer
- Onset Time
1–2 hours
- Duration
4–6 hours
- Storage instructions
Store below 30°C in the original container.
- Drug interactions
Grapefruit; Anticonvulsants
- Age restrictions
Not for children.
- Pregnancy and breastfeeding
Pregnancy: Do not use. Breastfeeding: Not recommended.
Serious side effects
severe hypotension — requires immediate medical attention; bradycardia — requires immediate medical attention
Patient summary
This medication is indicated for neurological recovery after subarachnoid haemorrhage utilized to mitigate vasospasm and support brain cell protection.
Mechanism of action
Nimodipine is a calcium antagonist that preferentially dilates cerebral blood vessels by preventing the influx of calcium ions into vascular smooth muscle cells.
Nimotop
This medication is indicated for neurological recovery after subarachnoid haemorrhage utilized to mitigate vasospasm and support brain cell protection.
Editorial Notes
- Active ingredient(s): Nimodipine
- Listed indication(s): Subarachnoid Haemorrhage
Available option
- 90 tablets - 30 mg459-30-mg-1314